Grifols | GRFS - Pre Tax Profit


Grifols reported EUR257.85M in Pre-Tax Profit for its fiscal quarter ending in December of 2024.





Pre Tax Profit Change Date
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Arca Biopharma USD -29.58M 694K Dec/2025
aTyr Pharma USD -25.75M 6.22M Sep/2025
Bio Path USD -976K 3.62M Sep/2025
Brainstorm Cell Therapeutics USD -2.11M 797K Sep/2025
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Grifols EUR 257.85M 190.87M Dec/2024
Immunic USD -21.38M 8.2M Jun/2024
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
TherapeuticsMD USD -1.05M 241K Jun/2024